Intelligence · Clinical Development
Pipeline search results
Programs matching “eli lilly” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 169 pipeline programs matching "eli lilly" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
I4V-MC-JAIP
Eli Lilly Co.
Atopic Dermatitis
1 trial -
I4V-MC-JAJJ
Eli Lilly Co.
Diabetes Mellitus, Type 1
1 trial -
I5T-MC-AACO
Eli Lilly Co.
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders
1 trial -
I6T-MC-AMAX
Eli Lilly Co.
Crohn’s Disease
1 trial -
I6T-MC-AMAY
Eli Lilly Co.
Crohn's Disease
1 trial -
I6T-MC-AMBA
Eli Lilly Co.
Moderately to Severely Active Ulcerative Colitis
1 trial -
I6T-MC-AMCD
Eli Lilly Co.
Obesity or Overweight, Ulcerative Colitis
1 trial -
I6T-MC-AMCE
Eli Lilly Co.
Obesity or Overweight, Crohn’s Disease
1 trial -
I8F-MC-GPGN
Eli Lilly Co.
Type 2 Diabetes Mellitus
1 trial -
I8F-MC-GPHP
Eli Lilly Co.
Obesity, Overweight
1 trial -
I8F-MC-GPIX
Eli Lilly Co.
Obesity
1 trial -
J1I-MC-GZBO
Eli Lilly Co.
Overweight, Obesity
1 trial -
J1I-MC-GZBP
Eli Lilly Co.
Obesity
1 trial -
J1I-MC-GZQD
Eli Lilly Co.
Overweight, Chronic Low Back Pain (CLBP), Obesity
1 trial -
J2A-MC-GZGW
Eli Lilly Co.
Type 2 Diabetes
1 trial -
J2A-MC-GZPL
Eli Lilly Co.
Hypertension
1 trial -
J2A-MC-GZPO
Eli Lilly Co.
GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes
1 trial -
J2A-MC-GZPR
Eli Lilly Co.
Peripheral Arterial Disease
1 trial -
J2A-MC-GZPS
Eli Lilly Co.
Urinary Incontinence, Stress
1 trial -
J2A-MC-GZPT
Eli Lilly Co.
Osteoarthritis
1 trial -
J2A-MC-GZPW
Eli Lilly Co.
Chronic Kidney Disease, Atherosclerosis Cardiovascular Disease
1 trial -
J2G-MC-JZJB
Eli Lilly Co.
RET-Mutant Medullary Thyroid Cancer
1 trial -
J2G-MC-JZJC
Eli Lilly Co.
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
1 trial -
J2G-MC-JZJX
Eli Lilly Co.
RET fusion-Positive NSCLC
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.